Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label randomized study of ribociclib plus endocrine therapy as adjuvant treatment for HR-positive, HER2-negative early breast cancer
CTR20191258Phase 3Active
- Sponsor
- Novartis
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ribociclib in breast cancer, sponsored by Novartis. Started Jul 2020; status: active.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20191258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191258.